Last reviewed · How we verify
NeoFuse
At a glance
| Generic name | NeoFuse |
|---|---|
| Also known as | Spinal Fusion, Stem Cells, Anterior Cervical Discectomy and Fusion with NeoFuse, Cervical Spinal Fusion, Adult Stem Cells |
| Sponsor | Mesoblast, Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion (PHASE2)
- Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF) (PHASE1, PHASE2)
- Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion (PHASE1, PHASE2)
- Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion (PHASE1, PHASE2)
- Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NeoFuse CI brief — competitive landscape report
- NeoFuse updates RSS · CI watch RSS
- Mesoblast, Ltd. portfolio CI